ABVC BioPharma (NASDAQ:ABVC – Get Free Report) and Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations and institutional ownership.
Analyst Ratings
This is a summary of recent ratings and recommmendations for ABVC BioPharma and Protagonist Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ABVC BioPharma | 1 | 0 | 0 | 0 | 1.00 |
| Protagonist Therapeutics | 1 | 1 | 13 | 0 | 2.80 |
Protagonist Therapeutics has a consensus target price of $113.69, suggesting a potential upside of 14.76%. Given Protagonist Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Protagonist Therapeutics is more favorable than ABVC BioPharma.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| ABVC BioPharma | N/A | -65.11% | -40.13% |
| Protagonist Therapeutics | -154.88% | -17.76% | -16.47% |
Earnings & Valuation
This table compares ABVC BioPharma and Protagonist Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ABVC BioPharma | $510,000.00 | 53.37 | -$7.91 million | ($0.40) | -2.68 |
| Protagonist Therapeutics | $46.02 million | 138.44 | -$130.15 million | ($1.81) | -54.73 |
ABVC BioPharma has higher earnings, but lower revenue than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
ABVC BioPharma has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500.
Summary
Protagonist Therapeutics beats ABVC BioPharma on 9 of the 14 factors compared between the two stocks.
About ABVC BioPharma
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Receive News & Ratings for ABVC BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABVC BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
